Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.
about
Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen.Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR studyFirst-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.The nutritional risk in oncology: a study of 1,453 cancer outpatientsNew insights into the role of age and carcinoembryonic antigen in the prognosis of colorectal cancer.Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?Comparison of colorectal and gastric cancer: survival and prognostic factors.Treatment of the elderly colorectal cancer patient: SIOG expert recommendations.Role of cetuximab in first-line treatment of metastatic colorectal cancerTreatment of colorectal cancer in older patients.Systemic treatment of gastrointestinal cancer in elderly patients.Variation by stage in the effects of prediagnosis weight loss on mortality in a prospective cohort of esophageal cancer patients.Synchronous colorectal liver metastases: focus on the elderly : An Effectiveness Study from Routine Care.Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy.Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients.Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy.Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer.Weight loss in cancer patients: a plea for a better awareness of the issue.Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy.Home parenteral nutrition improves quality of life and nutritional status in patients with cancer: a French observational multicentre study.Baseline mortality-adjusted survival in resected rectal cancer patients.
P2860
Q33778129-1D8AA08C-25A7-4AE1-A583-335AF4449799Q35584825-697BF87B-AF81-45C5-A6A6-167B2BF60732Q35863869-A787F046-BB40-4184-A023-A4D8FC7B7A97Q36078928-C7886203-3263-463E-B577-1474E9895066Q36614777-323A74D6-C0CF-4742-B172-594DDC4A8180Q36695795-FF101237-7037-4A18-BE43-D670426A07C5Q36964966-0A4C6E23-31E1-4B9B-9176-54F3942E0FAEQ37243626-5B2CF32D-8EB2-4815-9B36-F235B35DE048Q37298994-3B7E8C6A-659F-450B-BE66-5D1B63CA702BQ37708010-F73A4B49-20F9-462F-A439-CAB505889A33Q38050375-02629D79-E478-4DD2-840E-82FB687683D3Q38059634-1AFE411F-6F8C-4DCF-AD72-79930E0AB5ECQ38599598-5707458F-A999-4A12-BBF5-F9FAEC4561DEQ38627295-2DCFB095-A662-450D-ACA8-3E2882C9FFCDQ41044367-F7A531F1-878D-4723-BD9D-32567092537FQ42870892-99CA6E11-4796-4F75-805D-50B5546FE55AQ44808739-B29709B4-D8E7-4DF5-BBA4-7C2CD4E22E30Q46965188-64362355-0248-4D51-B3E7-1E9C8911A469Q47397575-B395A111-0B2B-4DC4-BDC5-4CA2F5D5F821Q47801764-74440015-30CA-4D90-918C-C0BC181AD47FQ48085258-529F534F-7665-4330-95CA-48C3A9DA434AQ51122988-B0122E8C-7CDD-431E-A53B-A743AB0C1861
P2860
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Predictive factors of survival ...... n irinotecan phase III trials.
@ast
Predictive factors of survival ...... n irinotecan phase III trials.
@en
type
label
Predictive factors of survival ...... n irinotecan phase III trials.
@ast
Predictive factors of survival ...... n irinotecan phase III trials.
@en
prefLabel
Predictive factors of survival ...... n irinotecan phase III trials.
@ast
Predictive factors of survival ...... n irinotecan phase III trials.
@en
P2093
P921
P356
P1433
P1476
Predictive factors of survival ...... n irinotecan phase III trials.
@en
P2093
D Mery-Mignard
E Magherini
E Van Cutsem
J-Y Douillard
P304
P356
10.1093/ANNONC/MDH267
P577
2004-07-01T00:00:00Z